TAFAZZIN Chromosome X
Tafazzin, phospholipid-lysophospholipid transacylase
Upload your DNA to see your personal genotypes for variants in TAFAZZIN.
What This Gene Does
This gene encodes a protein that is expressed at high levels in cardiac and skeletal muscle. Mutations in this gene have been associated with a number of clinical disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). Multiple transcript variants encoding different isoforms have been described. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. [provided by RefSeq, Jul 2008]
Associated Conditions (11)
Primary dilated cardiomyopathy
3-Methylglutaconic aciduria type 2
Endocardial fibroelastosis
Cardiovascular phenotype
TAFAZZIN-related disorder
Cardiomyopathy
Primary familial hypertrophic cardiomyopathy
Thyroid cancer
nonmedullary
1
Left ventricular noncompaction cardiomyopathy
Key Variants
RS1057515818
Conflicting classifications of pathogenicity
Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis
Health Risk
RS1223065368
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
Health Risk
RS1298362744
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS1557194488
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS200405157
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2
Health Risk
RS200909606
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis, Primary dilated cardiomyopathy
Health Risk
RS2522937677
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS2522986801
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder, 3-Methylglutaconic aciduria type 2
Health Risk
RS374146054
Conflicting classifications of pathogenicity
Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype
Health Risk
RS397515739
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS397515741
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
RS397515742
Conflicting classifications of pathogenicity
3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2
Health Risk
All Variants (109)
| RSID | Category | Clinical Significance | Conditions |
|---|---|---|---|
| RS1057515818 | Health Risk | Conflicting classifications of pathogenicity | Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis |
| RS1223065368 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2 |
| RS1298362744 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1557194488 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS200405157 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2 |
| RS200909606 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, Endocardial fibroelastosis, Primary dilated cardiomyopathy |
| RS2522937677 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522986801 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder, 3-Methylglutaconic aciduria type 2 |
| RS374146054 | Health Risk | Conflicting classifications of pathogenicity | Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype |
| RS397515739 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS397515741 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS397515742 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS397515745 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS397515746 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS397515750 | Health Risk | Conflicting classifications of pathogenicity | Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Primary dilated cardiomyopathy |
| RS62617809 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS727504327 | Health Risk | Conflicting classifications of pathogenicity | Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2, Primary dilated cardiomyopathy |
| RS781986219 | Health Risk | Conflicting classifications of pathogenicity | Endocardial fibroelastosis, 3-Methylglutaconic aciduria type 2, Primary dilated cardiomyopathy |
| RS782099193 | Health Risk | Conflicting classifications of pathogenicity | Cardiomyopathy, 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS782195445 | Health Risk | Conflicting classifications of pathogenicity | Cardiomyopathy, 3-Methylglutaconic aciduria type 2, TAFAZZIN-related disorder |
| RS782240044 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS782404246 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2 |
| RS782470471 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2 |
| RS782564325 | Health Risk | Conflicting classifications of pathogenicity | Endocardial fibroelastosis, Primary dilated cardiomyopathy, 3-Methylglutaconic aciduria type 2 |
| RS782653725 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, Cardiomyopathy, 3-Methylglutaconic aciduria type 2 |
| RS782731479 | Health Risk | Conflicting classifications of pathogenicity | Primary familial hypertrophic cardiomyopathy, 3-Methylglutaconic aciduria type 2, Primary familial hypertrophic cardiomyopathy |
| RS794729173 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS876661112 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS990648341 | Health Risk | Conflicting classifications of pathogenicity | 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, Thyroid cancer |
| RS104894942 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1057518416 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, Thyroid cancer, nonmedullary |
| RS1060500044 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1557191139 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1557194377 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1557194525 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1603376560 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1603376938 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS1603377936 | Health Risk | Likely pathogenic | Left ventricular noncompaction cardiomyopathy, Left ventricular noncompaction cardiomyopathy |
| RS1603377945 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, Cardiovascular phenotype, 3-Methylglutaconic aciduria type 2 |
| RS1603382251 | Health Risk | Likely pathogenic | — |
| RS2068331233 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2068570435 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2068574381 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2068606445 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2148186695 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2148194576 | Health Risk | Likely pathogenic | — |
| RS2522919648 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522923651 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522924351 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |
| RS2522924439 | Health Risk | Likely pathogenic | 3-Methylglutaconic aciduria type 2, 3-Methylglutaconic aciduria type 2 |